阿斯利康:巴昔多司他(Baxdrostat)在BaxHTN III期试验中达到主要终点和所有次要终点。 巴昔 多司他2毫

智通财经
Aug 30, 2025
阿斯利康:巴昔多司他(Baxdrostat)在BaxHTN III期试验中达到主要终点和所有次要终点。 巴昔 多司他2毫克剂量使收缩压较基线水平降低了15.7毫米汞柱(经安慰剂校正后为9.8毫米汞柱)。 巴昔多司他总体耐受性良好未发现意料之外的安全问题。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10